###### 

Resource table.

  --------------------------------------- -------------------------------------------------------------------------------------------------------------------------------
  Unique stem cell line identifier        TRNDi008-A

  Alternative name(s) of stem cell line   HT525A

  Institution                             National Institutes of Health\
                                          National Center for Advancing Translational Sciences\
                                          Bethesda, Maryland, USA

  Contact information of distributor      Dr. Wei Zheng\
                                          <Wei.Zheng@nih.gov>

  Type of cell line                       iPSC

  Origin                                  Human

  Additional origin info                  Age: 3-year-old\
                                          Sex: Male\
                                          Ethnicity: Caucasian

  Cell Source                             Skin fibroblasts

  Clonality                               Clonal

  Method of reprogramming                 Integration-free Sendai viral vectors

  Genetic Modification                    NO

  Type of Modification                    N/A

  Associated disease                      Mucopolysaccharidosis Type II

  Gene/locus                              Gene: IDS\
                                          Locus: Xq28\
                                          Mutation: c.208insC (p. H70PfsX29)

  Method of modification                  N/A

  Name of transgene or resistance         N/A

  Inducible/constitutive system           N/A

  Date archived/stock date                2018

  Cell line repository/bank               N/A

  Ethical approval                        NIGMS Informed Consent Form was obtained from patient at time of sample submission. Confidentiality Certificate: CC-GM-15-004
  --------------------------------------- -------------------------------------------------------------------------------------------------------------------------------

Resource utility {#S1}
================

The human induced pluripotent stem cells (hiPSC) described here is a useful tool that can be used to investigate disease phenotype and pathophysiology. As a potential cell-based disease model, these cells can be employed for drug development for the treatment of patients with MPS II.

Resource details {#S2}
================

MPS II is a rare X-linked genetic disease caused by mutations in the *IDS* gene encoding iduronate 2-sulfatase (I2S). The I2S enzyme is involved in the lysosomal degradation of two kinds of glycosaminoglycans (GAGs): heparan sulfate and dermatan sulfate ([@R2]). Malfunction of I2S leads to progressive accumulation of GAGs in tissues and organs, causing a variety of clinical symptoms in the patients. The typical manifestations of this disease include respiratory obstruction, cardiomyopathies, joint stiffness and hepatosplenomegaly. Some patients also have central nervous system (CNS) involvement, such as progressive neurological decline and cognitive impairment ([@R5]; [@R4]).

In this study, a human iPSC line was established from the fibroblasts of a 3-year-old male patient (GM13203, Coriell Institute) carrying a hemizygous mutation of a 1 bp insertion at nucleotide 208 in exon 2 (208insC) of the *IDS* gene, resulting in a frameshift with a premature stop codon (H70PfsX29). As described previously ([@R1]), the OCT3/4, KLF4, SOX2 and C-MYC pluripotency transcription factors were employed to transduce the patient fibroblasts into an iPSC line, named TRNDi008-A. The iPS cells exhibited classical embryonic stem cell morphology ([Fig. 1A](#F1){ref-type="fig"}), characterized by immunofluorescence staining and flow cytometry analysis and expressed major pluripotent protein markers of NANOG, SOX2, OCT4, SSEA4 and TRA-1-60 ([Fig. 1A](#F1){ref-type="fig"}, [B](#F1){ref-type="fig"}). Furthermore, G-banded karyotyping at passage 11 ([Fig. 1C](#F1){ref-type="fig"}) confirmed a normal karyotype (46, XY). The mutation (208insC) in the *IDS* gene was also verified by Sanger sequencing of the PCR product harboring the single nucleotide variation (SNV) ([Fig. 1D](#F1){ref-type="fig"}). Sendai virus vector (SeV) clearance was determined with reverse transcription polymerase chain reaction (RT-PCR) using SeV-specific primers and the vector disappeared by passage 15 ([Fig. 1E](#F1){ref-type="fig"}). Mycoplasma status was confirmed to be negative ([Supplementary Fig. S1](#SD1){ref-type="supplementary-material"}) and the cell line was authenticated using STR DNA profiling analysis, which demonstrated matching genotypes at all 18 loci examined (information available with the authors). Finally, pluripotency of TRNDi008-A was confirmed by a teratoma formation experiment, which exhibited the ability to differentiate into all three germ layers (ectoderm, neural tube; mesoderm, smooth muscle; endoderm, gut) *in vivo* ([Fig. 1F](#F1){ref-type="fig"})([Table 1](#T1){ref-type="table"}).

Materials and methods {#S3}
=====================

Cell culture {#S4}
------------

Patient-derived fibroblasts (GM13203, Coriell Institute) were cultured in DMEM supplemented with 10% fetal bovine serum, 100 units/ml penicillin and 100 μg/ml streptomycin in a humidified incubator with 5% CO~2~ at 37 °C. Human iPS cells were cultured in StemFlex medium (ThermoFisher) on matrigel (Corning, 354,277)-coated plates at 37 °C in humidified air with 5% CO~2~ and 5% O~2~. Cells were passaged with 0.5 mM Ethylenediaminetetraacetic acid (EDTA) upon approaching 80% confluency.

Reprogramming of human skin fibroblasts {#S5}
---------------------------------------

As described previously ([@R3]), patient fibroblasts were reprogrammed into iPS cells using non-integrating Sendai virus vector technology (A16517, ThermoFisher).

Genome analysis {#S6}
---------------

Genomic analysis of IDS variants was performed by Applied StemCell (Milpitas, California). Briefly, QuickExtract^™^ DNA Extraction Solution (Lucigen) was used to extract genomic DNA from TRNDi008-A cells. PCR amplifications (MyTaq^™^ Red Mix, Bioline) were carried out on a T00 Thermal Cycler (Bio-Rad) using the following program: 95 °C, 2 mins; 35 cycles of \[95 °C, 15 s; 60 °C, 15 s; 72 °C\], elongation duration varies by amplicon size, 72 °C 5 mins; 4 °C, indefinite. Sanger sequencing analysis was performed for genotyping of the hemizygous mutation of a 1 bp insertion at nucleotide 208 in exon 2 of the *IDS* gene. The specific primers for gene amplification and sequencing are listed in [Table 2](#T2){ref-type="table"}.

Immunocytochemistry {#S7}
-------------------

Patient-derived iPSCs were fixed for 15 mins in 4% paraformaldehyde, washed with Dulbecco's Phosphate-Buffered Saline (DPBS), permeabilized with 0.5% Triton X-100 in DPBS (10 mins), followed by incubation with Image-iT^™^ FX signal enhancer (ThermoFisher) for 40 mins at ambient temperature in a humidified environment. Primary antibodies (SOX2, OCT4, NANOG and SSEA4) were diluted in the Image-iT^™^ FX signal enhancer blocking buffer and then incubated with the cells overnight at 4 °C. Following a DPBS wash, corresponding secondary antibodies conjugated with Alexa Fluor 488 or Alex Fluor 594 were added and incubated for 1 h at ambient temperature ([Table 2](#T2){ref-type="table"}). Cells were stained with Hoechst 33342 (15 mins), washed, and imaged using an INCell Analyzer 2200 (GE Healthcare) and a 20× objective lens with Texas Red, FITC and DAPI filter sets.

Flow cytometry analysis {#S8}
-----------------------

Human iPSCs were dissociated using TrypLE solution (Thermo Fisher) then fixed and permeabilized for intracellular staining as described previously \[[@R5]\]. The fluorophore conjugated antibodies used in this protocol are listed in [Table 2](#T2){ref-type="table"}. Samples were analyzed by an AccuriC6 Flow Cytometry system (BD Biosciences).

G-banded karyotyping {#S9}
--------------------

Karyotype analysis was performed by WiCell Research Institute (Madison, WI). Twenty randomly selected metaphases were selected and analyzed using G-banding method.

Short tandem repeat (STR) analysis {#S10}
----------------------------------

STR analysis of the patient-derived fibroblasts and patient iPS cells was conducted by the Johns Hopkins University Genetic Resources Facility using a PowerPlex 18D Kit (Promega). The PCR products were electrophoresed on an ABI Prism^®^ 3730x1 Genetic Analyzer. GeneMapper^®^ v 4.0 software (Applied Biosystems) was used to analyze data.

Mycoplasma detection {#S11}
--------------------

Mycoplasma status was assessed using the MycoAlert kit (Lonza) per manufacturer instructions. A ratiometric reading of \< 0.9 indicates a mycoplasma negative sample.

Testing for Sendai reprogramming vector clearance {#S12}
-------------------------------------------------

Human fibroblasts (GM05659, Coriell) were transfected with Sendai virus for 4 days and used as the positive control. Total RNA was extracted using RNeasy Plus Mini Kit (Qiagen) and 1 μg of RNA was reverse transcribed into cDNA with Superscript^™^ III First-Strand Synthesis SuperMix kit. PCR was performed using Platinum II Hot-Start PCR Master Mix (ThermoFisher) and the amplifications were carried out as previously described ([@R3]) using the primers listed in [Table 2](#T2){ref-type="table"}. Products were then loaded to the *E*-Gel^®^ 1.2% with SYBR Safe^™^ gel and imaged using a G: Box Chemi-XX6 gel doc system (Syngene).

Teratoma formation assay {#S13}
------------------------

TRNDi008-A cells were dissociated from 6-well plates using 0.5 mM EDTA in DPBS. A suspension of 1 × 10^7^ cells in 400 μl medium supplied with 25 mM HEPES (pH 7.4) was kept on ice, and then added with a 50% volume (200 μl) of cold Matrigel (Corning, 354277). The mixture was injected subcutaneously into NSG mice (JAX No. 005557) at 150 μl per injection site. After 6--8 weeks, visible tumors were removed and fixed in 10% Neutral Buffer Formalin. The fixed tumors were embedded in paraffin and stained with hematoxylin and eosin.

Supplementary Material {#SM1}
======================

We would like to thank Dr. Zu-xi Yu of the pathology Core of National Heart, Lung and Blood Institute, National Institutes of Health for sectioning and staining the teratoma. We also would like to thank the Research Services Section at National Center for Advancing Translational Sciences for coordinating the STR DNA analysis and mycoplasma testing service. This work was supported by the Intramural Research Program of National Center for Advancing Translational Sciences, National Institutes of Health.

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.scr.2019.101451>.

![Characterization of TRNDi008-A iPSC line A) From left to right: phase contrast imaging of TRNDi008-A colonies; immunostained TRNDi008-A iPSCs expressing SOX2, OCT4, NANOG and SSEA4. Hoeschst (blue) was used to label the nucleus. B) Pluripotency protein markers (TRA-1-60, NANOG and SSEA4) were assessed by flow cytometry. C) G-banding karyotype analysis confirmed normal karyotype (46, XY). D) Sanger sequencing was used to confirm the mutation in exon 2 of the IDS gene (208insC). E) RT-PCR verification of Sendai virus clearance in TRNDi008-A iPSC line. SeV transduced fibroblasts were used as positive control. F) Histological characterization of teratoma formation, showing normal ectoderm, endoderm and mesoderm differentiation.](nihms-1530899-f0001){#F1}

###### 

Characterization and validation.

  Classification                        Test                                   Result                                                                                                                                                    Data
  ------------------------------------- -------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------
  Morphology                            Photography                            Normal                                                                                                                                                    [Fig. 1](#F1){ref-type="fig"} Panel A
  Phenotype                             Immunocytochemistry                    SOX2, OCT4, NANOG, SSEA-4                                                                                                                                 [Fig. 1](#F1){ref-type="fig"} Panel A
                                        Flow cytometry                         TRA-1-60 (99.97%); NANOG (93.26%); SSEA-4 (100%)                                                                                                          [Fig. 1](#F1){ref-type="fig"} Panel B
  Genotype                              Karyotype (G-banding) and resolution   46XY                                                                                                                                                      [Fig. 1](#F1){ref-type="fig"} Panel C
                                                                               Resolution: 350--400                                                                                                                                      
  Identity                              Microsatellite PCR (mPCR) OR           Not performed                                                                                                                                             N/A
                                        STR analysis                           18 sites tested, all sites matched                                                                                                                        Available with the authors
  Mutation analysis (IF APPLICABLE)     Sequencing                             Hemizygous mutation of IDS                                                                                                                                [Fig. 1](#F1){ref-type="fig"} Panel D
                                        Southern Blot OR WGS                   N/A                                                                                                                                                       N/A
  Microbiology and virology             Mycoplasma                             Mycoplasma testing by luminescence. Negative Teratoma with three germlayers formation. Ectoderm (neural tube); Mesoderm (smooth muscle); Endoderm (gut)   [Supplementary Fig. S1](#SD1){ref-type="supplementary-material"}
  Differentiation potential             Teratoma formation                     [Fig. 1](#F1){ref-type="fig"} Panel F                                                                                                                     
  Donor screening (OPTIONAL)            HIV 1 + 2 Hepatitis B, Hepatitis C     N/A                                                                                                                                                       N/A
  Genotype additional info (OPTIONAL)   Blood group genotyping                 N/A                                                                                                                                                       N/A
  HLA tissue typing                     N/A                                    N/A                                                                                                                                                       

###### 

Reagents details

  Antibodies used for immunocytochemistry/flow-cytometry                                                       
  -------------------------------------------------------- ------------------------------------------ -------- ------------------------------------------------------------------------------------------------------
  Pluripotency Markers                                     Mouse anti-SOX2                            1:50     R & D systems, Cat\# MAB2018, RRID: [AB_358009](http://antibodyregistry.org/AB_358009)
  Pluripotency Markers                                     Rabbit anti-NANOG                          1:400    Cell Signaling Technology, Cat\# 4903, RRID: [AB_10559205](http://antibodyregistry.org/AB_10559205)
  Pluripotency Markers                                     Rabbit anti-OCT4                           1:400    Thermo Fisher, Cat\# A13998, RRID: [AB_2534182](http://antibodyregistry.org/AB_2534182)
  Pluripotency Markers                                     Mouse anti-SSEA4                           1:1000   Cell Signaling Technology, Cat\# 4755, RRID: [AB_1264259](http://antibodyregistry.org/AB_1264259)
  Secondary Antibodies                                     Donkey anti-Mouse IgG (Alexa Fluor 488)    1:400    Thermo Fischer, Cat\# A21202, RRID: [AB_141607](http://antibodyregistry.org/AB_141607)
  Secondary Antibodies                                     Donkey anti-Rabbit IgG (Alexa Fluor 594)   1:400    Thermo Fischer, Cat\# A21207, RRID: [AB_141637](http://antibodyregistry.org/AB_141637)
  Flow Cytometry Antibodies                                Anti-Tra-1-60-DyLight 488                  1:50     Thermo Fischer, Cat\# MA1--023-D488X, RRID: [AB_2536700](http://antibodyregistry.org/AB_2536700)
  Flow Cytometry Antibodies                                Anti-Nanog-Alexa Fluor 488                 1:50     Millipore, Cat\# FCABS352A4, RRID: [AB_10807973](http://antibodyregistry.org/AB_10807973)
  Flow Cytometry Antibodies                                anti-SSEA-4-Alexa Fluor 488                1:50     Thermo Fischer, Cat\# 53-8843-41, RRID: [AB_10597752](http://antibodyregistry.org/AB_10597752)
  Flow Cytometry Antibodies                                Mouse-IgM-DyLight 488                      1:50     Thermo Fischer, Cat\# MA1-194-D488, RRID: [AB_2536969](http://antibodyregistry.org/AB_2536969)
  Flow Cytometry Antibodies                                Rabbit IgG-Alexa Fluor 488                 1:50     Cell Signaling Technology, Cat\# 4340S, RRID: [AB_10694568](http://antibodyregistry.org/AB_10694568)
  Flow Cytometry Antibodies                                Mouse IgG3-FITC                            1:50     Thermo Fischer, Cat\# 11-4742-42, RRID: [AB_2043894](http://antibodyregistry.org/AB_2043894)

  Primers                                                   
  ---------------------------------- ---------------------- ----------------------------------------------------------------------
  Sev specific primers (RT-PCR)      Sev/181 bp             GGA TCA CTA GGT GAT ATC GAG C/ACC AGA CAA GAG TTT AAG AGA TAT GTA TC
  Sev specific primers (RT-PCR)      KOS/528 bp             ATG CAC CGC TAC GAC GTG AGC GC/ACC TTG ACA ATC CTG ATG TGG
  Sev specific primers (RT-PCR)      Klf4/410 bp            TTC CTG CAT GCC AGA GGA GCC C/AAT GTA TCG AAG GTG CTC AA
  Sev specific primers (RT-PCR)      C-Myc/523 bp           TAA CTG ACT AGC AGG CTT GTC G/TCC ACA TAC AGT CCT GGA TGA TGA TG
  House-Keeping gene (RT-PCR)        GAPDH/197 bp           GGA GCG AGA TCC CTC CAA AAT/GGC TGT TGT CAT ACT TCT CAT GG
  Targeted mutation analysis (PCR)   IDS (208insC)/357 bp   CGC ACA ATC TGT GCC ATC TG/TGG CTA GGC TGT TAA GGT GC
